Lv, M.; Huang, T.; Mo, X.-D.; Sun, Y.-Q.; Chang, Y.-J.; Xu, L.-P.; Zhang, X.-H.; Huang, X.-J.; Wang, Y.
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancers 2025, 17, 1364.
https://doi.org/10.3390/cancers17081364
AMA Style
Lv M, Huang T, Mo X-D, Sun Y-Q, Chang Y-J, Xu L-P, Zhang X-H, Huang X-J, Wang Y.
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancers. 2025; 17(8):1364.
https://doi.org/10.3390/cancers17081364
Chicago/Turabian Style
Lv, Meng, Ting Huang, Xiao-Dong Mo, Yu-Qian Sun, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, and Yu Wang.
2025. "Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation" Cancers 17, no. 8: 1364.
https://doi.org/10.3390/cancers17081364
APA Style
Lv, M., Huang, T., Mo, X.-D., Sun, Y.-Q., Chang, Y.-J., Xu, L.-P., Zhang, X.-H., Huang, X.-J., & Wang, Y.
(2025). Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancers, 17(8), 1364.
https://doi.org/10.3390/cancers17081364
